Quitting and restarting smoking: cohort study of patients with angina in primary care.
diary cards for severity of dyspeptic symptoms in patients with non-ulcer dyspepsia. Eur J Surg 1998;164(suppl 583):106-11. 10 Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clin Trials 1989;10:407-15. 11 Wiklund IK, Junghard O, Grace E, Talley NJ, Kamm M, Veldhuyzen van Zanten SJO, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg 1998;164(suppl 583):41-9. 12 Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Cost benefit analysis. In: Methods for the economic evaluation of health care programmes. New York: Oxford Medical Publications, Oxford University Press, 1997:205-31. 13 Labour force and unpaid work of Canadians: selected labour force, demographic, cultural, educational and income characteristics by sex (based on the 1991 standard occupational classification) for Canadian provinces, territories and CMAs, 1996 census (20% sample data). Ottawa, Canada: Statistics Canada, 1996. 14 Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-200. 15 Vinod HD. Bootstrap methods: applications in econometrics. In: Maddala GS, Rao CR, Vinod HD, eds. Handbook of statistics 11: econometrics. Elsevier Science, Chapman and Hall, CRC, 1993:629-61. 16 Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79. 17 Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection [see comments]. Lancet 1995;345:1591-4. 18 Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;134:361-9. 19 Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ 2000;321:659-64. 20 Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999;45(suppl 2):II37-42. 21 Tytgat GN. GERD remains an intriguing enigma. Gastroenterology 2001;120:787. 22 McColl KEL, Dickson A, El-Nujumi A, el-Omar E, Kelman A. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:101-5. 23 Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-6. 24 Chiba N, Veldhuyzen van Zanten SJO, Grace EM, Sinclair P, Simons WR, Lee JSM. The cost-effectiveness of a test and treat approach in primary care patients. Gut 2000;47(suppl 1):A113-4.